Virtus ETF Advisers LLC Has $255,000 Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Virtus ETF Advisers LLC trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 47.9% during the second quarter, Holdings Channel.com reports. The firm owned 2,214 shares of the biotechnology company’s stock after selling 2,036 shares during the period. Virtus ETF Advisers LLC’s holdings in Ascendis Pharma A/S were worth $255,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ASND. LPL Financial LLC raised its stake in shares of Ascendis Pharma A/S by 6.2% during the second quarter. LPL Financial LLC now owns 2,233 shares of the biotechnology company’s stock worth $257,000 after buying an additional 131 shares during the last quarter. Flinton Capital Management LLC raised its stake in shares of Ascendis Pharma A/S by 6.7% during the second quarter. Flinton Capital Management LLC now owns 2,304 shares of the biotechnology company’s stock worth $265,000 after buying an additional 144 shares during the last quarter. Aperio Group LLC raised its stake in shares of Ascendis Pharma A/S by 3.3% during the second quarter. Aperio Group LLC now owns 4,582 shares of the biotechnology company’s stock worth $528,000 after buying an additional 147 shares during the last quarter. Comerica Bank raised its stake in shares of Ascendis Pharma A/S by 7.8% during the second quarter. Comerica Bank now owns 2,460 shares of the biotechnology company’s stock worth $277,000 after buying an additional 179 shares during the last quarter. Finally, Meadow Creek Investment Management LLC raised its stake in shares of Ascendis Pharma A/S by 6.7% during the second quarter. Meadow Creek Investment Management LLC now owns 3,168 shares of the biotechnology company’s stock worth $365,000 after buying an additional 198 shares during the last quarter.

NASDAQ:ASND traded down $0.85 during trading hours on Friday, hitting $103.72. The stock had a trading volume of 213,221 shares, compared to its average volume of 215,087. Ascendis Pharma A/S has a one year low of $53.21 and a one year high of $133.96. The company has a debt-to-equity ratio of 0.05, a quick ratio of 11.59 and a current ratio of 11.59. The company has a market cap of $4.41 billion, a price-to-earnings ratio of -27.73 and a beta of 0.64. The business’s 50 day moving average is $112.88 and its 200-day moving average is $115.65.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.08). Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. The firm had revenue of $3.61 million during the quarter, compared to the consensus estimate of $0.68 million. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -5.31 EPS for the current fiscal year.

ASND has been the subject of a number of recent research reports. Canaccord Genuity boosted their price target on shares of Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. Wedbush reaffirmed a “buy” rating and issued a $223.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, June 28th. Zacks Investment Research raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, August 27th. BidaskClub downgraded shares of Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $143.00 to $152.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus target price of $153.29.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.